WO2017032815A2 - Biomarqueurs pour maladies cardiométaboliques - Google Patents

Biomarqueurs pour maladies cardiométaboliques Download PDF

Info

Publication number
WO2017032815A2
WO2017032815A2 PCT/EP2016/070011 EP2016070011W WO2017032815A2 WO 2017032815 A2 WO2017032815 A2 WO 2017032815A2 EP 2016070011 W EP2016070011 W EP 2016070011W WO 2017032815 A2 WO2017032815 A2 WO 2017032815A2
Authority
WO
WIPO (PCT)
Prior art keywords
protein
amount
masp
mrna
proteins
Prior art date
Application number
PCT/EP2016/070011
Other languages
English (en)
Other versions
WO2017032815A3 (fr
Inventor
Christine VON TÖRNE
Stefanie M. HAUCK
Cornelia HUTH
Barbara THORAND
Tonia DE LAS HERAS GALA
Original Assignee
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) filed Critical Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Publication of WO2017032815A2 publication Critical patent/WO2017032815A2/fr
Publication of WO2017032815A3 publication Critical patent/WO2017032815A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Abstract

La présente invention concerne un procédé pour identifier une prédisposition au développement du diabète sucré de type 2 chez un sujet, ou pour produire une valeur à visée d'information diagnostique concernant la quantité d'une ou de plusieurs protéines ou d'un ou de plusieurs ARNm codant ladite ou lesdites protéines pour identifier une prédisposition au développement d'un diabète sucré de type 2, ledit procédé comprenant ou étant constitué de (i) l'évaluation dans un échantillon obtenu auprès dudit sujet de la quantité d'un ou de plusieurs protéines et/ou d'un ou de plusieurs ARNm codant ladite ou lesdites protéines, ladite ou lesdites protéines étant choisies dans un groupe de protéines défini dans ce qui suit, et (ii) la détermination des paramètres dudit sujet, dans lequel (a) lesdits paramètres sont l'âge et le sexe, et ledit groupe est constitué de AP0C2, AP0C3, APOE, CRP, MASP-1, ADIPOQ, ΙΤΊΗ4 et SHBG; (b) lesdits paramètres sont l'âge, le sexe et l'IMC, et ledit groupe est constitué de AP0C2, AP0C3, APOE, MASP-1, ADIPOQ, ITIH4, PZP et SHBG; ou (c) lesdits paramètres sont l'âge, le sexe, l'IMC, le statut de tabagisme, la consommation d'alcool, l'inactivité physique, l'hypertension réelle, les teneurs en triacylglycérol transformées en log10 et le rapport cholestérol total/HDL-cholestérol transformé en log10 et ledit groupe est constitué de MASP-1, ADIPOQ, ITIH4, ORM1 et PZP; dans lequel une augmentation de la quantité d'APOC2, APOC3, APOE, de CRP ou de MASP-1 ou d'un ARNm codant APOC2, APOC3, APOE, CRP ou MASP-1 ou une diminution de la quantité d'ADIPOQ, ITIH4, SHBG, PZP ou ORM1 ou d'un ARNm codant ADIPOQ, ITIH4, SHBG, PZP ou ORM1 par rapport à la quantité de ladite ou desdites protéines ou dudit ou desdits ARNm, respectivement, d'un témoin, indique une prédisposition à développer un diabète sucré de type 2.
PCT/EP2016/070011 2015-08-24 2016-08-24 Biomarqueurs pour maladies cardiométaboliques WO2017032815A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15182201 2015-08-24
EP15182201.2 2015-08-24

Publications (2)

Publication Number Publication Date
WO2017032815A2 true WO2017032815A2 (fr) 2017-03-02
WO2017032815A3 WO2017032815A3 (fr) 2017-05-04

Family

ID=54007573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/070011 WO2017032815A2 (fr) 2015-08-24 2016-08-24 Biomarqueurs pour maladies cardiométaboliques

Country Status (1)

Country Link
WO (1) WO2017032815A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107024590A (zh) * 2017-03-13 2017-08-08 新疆医科大学 一种诊断1型和2型糖尿病的血清蛋白标志物组
WO2021142200A1 (fr) * 2020-01-10 2021-07-15 Somalogic, Inc. Méthodes de détermination d'une intolérance au glucose
KR20210099207A (ko) * 2016-07-21 2021-08-11 클리블랜드 하트랩, 아이엔씨. Hdl-관련 단백질 바이오마커 패널 검출
JP2022512602A (ja) * 2018-10-04 2022-02-07 コリア アドヴァンスド インスティテュート オブ サイエンス アンド テクノロジー 活性成分としてｔｓｐ１タンパク質インヒビターを含有する、ファブリー病を予防または処置するための医薬組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009064901A2 (fr) * 2007-11-13 2009-05-22 Veridex, Llc Biomarqueurs diagnostiques du diabète

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009064901A2 (fr) * 2007-11-13 2009-05-22 Veridex, Llc Biomarqueurs diagnostiques du diabète

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALTAN ONAT ET AL: "-482C>T polymorphism, circulating apolipoprotein C-III and smoking: Interrelation and roles in predicting type-2 diabetes and coronary disease", CLINICAL BIOCHEMISTRY, ELSEVIER INC, US, CA, vol. 44, no. 5, 13 December 2010 (2010-12-13), pages 391 - 396, XP028366827, ISSN: 0009-9120, [retrieved on 20101223], DOI: 10.1016/J.CLINBIOCHEM.2010.12.009 *
ANNE HIUKKA ET AL: "Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes", DIABETOLOGIA ; CLINICAL AND EXPERIMENTAL DIABETES AND METABOLISM, SPRINGER, BERLIN, DE, vol. 48, no. 6, 1 June 2005 (2005-06-01), pages 1207 - 1215, XP019322561, ISSN: 1432-0428, DOI: 10.1007/S00125-005-1753-Z *
KOLBERG JANICE A ET AL: "Biomarkers in Type 2 diabetes: improving risk stratification with the PreDx (R) Diabetes Risk Score", EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, EXPERT REVIEWS LTD, GB, vol. 11, no. 8, 1 November 2011 (2011-11-01), pages 775 - 792, XP009190929, ISSN: 1744-8352, DOI: 10.1586/ERM.11.63 *
L. JENNY ET AL: "Plasma levels of mannan-binding lectin-associated serine proteases MASP-1 and MASP-2 are elevated in type 1 diabetes and correlate with glycaemic control", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 180, no. 2, 14 May 2015 (2015-05-14), GB, pages 227 - 232, XP055356240, ISSN: 0009-9104, DOI: 10.1111/cei.12574 *
S. BÉLIARD ET AL: "Parallel increase of plasma apoproteins C-II and C-III in Type 2 diabetic patients", DIABETIC MEDICINE., vol. 26, no. 7, 1 July 2009 (2009-07-01), GB, pages 736 - 739, XP055322154, ISSN: 0742-3071, DOI: 10.1111/j.1464-5491.2009.02757.x *
SABANAYAGAM C ET AL: "Serum C-reactive protein level and prediabetes in two Asian populations", DIABETOLOGIA ; CLINICAL AND EXPERIMENTAL DIABETES AND METABOLISM, SPRINGER, BERLIN, DE, vol. 54, no. 4, 26 January 2011 (2011-01-26), pages 767 - 775, XP019888877, ISSN: 1432-0428, DOI: 10.1007/S00125-011-2052-5 *
TOERNE CHRISTINE VON ET AL: "MASP1, THBS1, GPLD1 and ApoA-IV are novel biomarkers associated with prediabetes: the KORA F4 study", DIABETOLOGIA, SPRINGER, BERLIN, DE, vol. 59, no. 9, 25 June 2016 (2016-06-25), pages 1882 - 1892, XP036020160, ISSN: 0012-186X, [retrieved on 20160625], DOI: 10.1007/S00125-016-4024-2 *
V. FRAUENKNECHT ET AL: "Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 173, no. 1, 6 July 2013 (2013-07-06), GB, pages 112 - 120, XP055356242, ISSN: 0009-9104, DOI: 10.1111/cei.12093 *
VEIKKO SALOMAA ET AL: "Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes", PLOS ONE, vol. 5, no. 4, 9 April 2010 (2010-04-09), pages e10100, XP055106003, DOI: 10.1371/journal.pone.0010100 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210099207A (ko) * 2016-07-21 2021-08-11 클리블랜드 하트랩, 아이엔씨. Hdl-관련 단백질 바이오마커 패널 검출
KR102424550B1 (ko) 2016-07-21 2022-07-22 클리블랜드 하트랩, 아이엔씨. Hdl-관련 단백질 바이오마커 패널 검출
CN107024590A (zh) * 2017-03-13 2017-08-08 新疆医科大学 一种诊断1型和2型糖尿病的血清蛋白标志物组
JP2022512602A (ja) * 2018-10-04 2022-02-07 コリア アドヴァンスド インスティテュート オブ サイエンス アンド テクノロジー 活性成分としてｔｓｐ１タンパク質インヒビターを含有する、ファブリー病を予防または処置するための医薬組成物
WO2021142200A1 (fr) * 2020-01-10 2021-07-15 Somalogic, Inc. Méthodes de détermination d'une intolérance au glucose

Also Published As

Publication number Publication date
WO2017032815A3 (fr) 2017-05-04

Similar Documents

Publication Publication Date Title
US9546994B2 (en) Biomarkers for type 2 diabetes
Ye et al. Plasma miR-17, miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients
EP3082840B1 (fr) Méthodes et dosages biologiques se rapportant à des cellules tumorales circulantes
Hunt et al. Integrated genomic and proteomic analyses identify stimulus-dependent molecular changes associated with distinct modes of skeletal muscle atrophy
WO2017032815A2 (fr) Biomarqueurs pour maladies cardiométaboliques
EP2334816B1 (fr) Gènes associés à un trouble de stress post-traumatique (ptsd)
Krishnan et al. Liver pyruvate kinase promotes NAFLD/NASH in both mice and humans in a sex-specific manner
Barutta et al. Novel biomarkers of diabetic kidney disease: current status and potential clinical application
KR20200040848A (ko) 비알콜성 지방 간 질환, 비알콜성 지방간염 및/또는 간 섬유화의 비침습성 진단
JP2021502109A (ja) 非アルコール性脂肪性肝疾患、非アルコール性脂肪性肝炎、及び／又は肝線維症の非侵襲的診断
Yin et al. The epitranscriptome of long noncoding RNAs in metabolic diseases
Takeuchi et al. Comprehensive analysis of serum microRNAs in hepatic sinusoidal obstruction syndrome (SOS) in rats: implication as early phase biomarkers for SOS
Aboumsallem et al. Multi-omics analyses identify molecular signatures with prognostic values in different heart failure aetiologies
Chu et al. microRNA-103a-3p promotes inflammation and fibrosis in nonalcoholic fatty liver disease by targeting HBP1
Zhou et al. Circulating microRNA profile as a potential predictive biomarker for early diagnosis of spontaneous abortion in patients with subclinical hypothyroidism
EP3011341B1 (fr) Traitement de la résistance à l'insuline par des inhibiteurs du facteur de transcription tsc22d4
CN114582509A (zh) 一种葡萄膜黑色素瘤预后风险评分模型及其应用
US11874277B2 (en) Systems and methods for Barrett's esophagus pathogenesis and esophageal adenocarcinoma progression revealing markers
Najimi et al. Exploring the role of tryptophanyl-tRNA synthetase and associations with inflammatory markers and clinical outcomes in COVID-19 patients: A case-control study
CN116287272B (zh) Prdx5在诊断及治疗胶质瘤中的应用
Chella Krishnan et al. Liver Pyruvate Kinase Promotes NAFLD/NASH in Both Mice and Humans in a Sex-Specific
Nilsson et al. OPEN ACCESS EDITED BY
Chen et al. Inflammation Related lncNOS2P3-miR-939-5p-iNOS/TNFα Pathway Inhibits Myocardial and Endothelial Cells Apoptosis in Chronic Heart Failure
Matsumoto et al. Clinical/Translational Research

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16760417

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16760417

Country of ref document: EP

Kind code of ref document: A2